Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists
Identifieur interne : 000F75 ( Istex/Corpus ); précédent : 000F74; suivant : 000F76Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists
Auteurs : C. Anthony Hubbard ; TrugmanSource :
- Movement Disorders [ 0885-3185 ] ; 1993.
English descriptors
Abstract
To gain insight into the antiparkinsonian effects of selective D1 and D2 dopamine receptor stimulation, we examined the ability of D1 (SKF 38393) and D2 (quinpirole) agonists to reverse catalepsy induced by the combined administration of reserpine and α‐methyl‐p‐tyrosine (AMPT) in rats. Catalepsy, the failure to correct an externally imposed posture, is a measure of akinesia and was assessed using the bar test. Rats injected with reserpine alone (2.5 mg/ kg i.p.) developed akinesia and ptosis within 60‐90 min. The D1 agonist SKF 38393 (30 mg/ kg i.v.) rapidly reversed ptosis and restored near‐normal mobility when administered 24 h after reserpine and AMPT; catalepsy was reversed for 90 min, after which the drug effect wore off. Quinpirole (1 mg/ kg i.v.) reversed catalepsy for the duration of the test period (4 h) but did not consistently reverse ptosis or promote normal mobility; the rats continued to exhibit kyphotic postures with little spontaneous locomotion. These results indicate that selective D1 stimulation is sufficient to reverse reserpine‐induced akinesia and highlight the need for the development of potent selective D1 agonists for clincal traial in Parkinson's disease. In serve dopamine depletion, D2 stimulation alone appears to be insufficient to restore normal movement. Quinpirole, but not SKF 38393, elicited paroxysmal limb/ body jerking in reserpine‐AMPT‐treated rats, providing further evidence that atypical jerking can be elicited by D2 stimulation in the complete absence of D1 stimulation. This laboratory observation suggests that some jerking dyskinesias seen in treated parkinsonian patients may be mediated by an imbalance in D1‐D2 receptor stimulation.
Url:
DOI: 10.1002/mds.870080410
Links to Exploration step
ISTEX:A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title><author><name sortKey="Hubbard, C Anthony" sort="Hubbard, C Anthony" uniqKey="Hubbard C" first="C. Anthony" last="Hubbard">C. Anthony Hubbard</name><affiliation><mods:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Trugman" sort="Trugman" uniqKey="Trugman" last="Trugman">Trugman</name><affiliation><mods:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1002/mds.870080410</idno><idno type="url">https://api.istex.fr/document/A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title><author><name sortKey="Hubbard, C Anthony" sort="Hubbard, C Anthony" uniqKey="Hubbard C" first="C. Anthony" last="Hubbard">C. Anthony Hubbard</name><affiliation><mods:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Trugman" sort="Trugman" uniqKey="Trugman" last="Trugman">Trugman</name><affiliation><mods:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993">1993</date><biblScope unit="vol">8</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="473">473</biblScope><biblScope unit="page" to="478">478</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2</idno><idno type="DOI">10.1002/mds.870080410</idno><idno type="ArticleID">MDS870080410</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Catalepsy</term><term>D1 and D2 dopamine agonist</term><term>Parkinsonism</term><term>Rat</term><term>Reserpine</term><term>α‐Methyl‐p‐tyrosine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To gain insight into the antiparkinsonian effects of selective D1 and D2 dopamine receptor stimulation, we examined the ability of D1 (SKF 38393) and D2 (quinpirole) agonists to reverse catalepsy induced by the combined administration of reserpine and α‐methyl‐p‐tyrosine (AMPT) in rats. Catalepsy, the failure to correct an externally imposed posture, is a measure of akinesia and was assessed using the bar test. Rats injected with reserpine alone (2.5 mg/ kg i.p.) developed akinesia and ptosis within 60‐90 min. The D1 agonist SKF 38393 (30 mg/ kg i.v.) rapidly reversed ptosis and restored near‐normal mobility when administered 24 h after reserpine and AMPT; catalepsy was reversed for 90 min, after which the drug effect wore off. Quinpirole (1 mg/ kg i.v.) reversed catalepsy for the duration of the test period (4 h) but did not consistently reverse ptosis or promote normal mobility; the rats continued to exhibit kyphotic postures with little spontaneous locomotion. These results indicate that selective D1 stimulation is sufficient to reverse reserpine‐induced akinesia and highlight the need for the development of potent selective D1 agonists for clincal traial in Parkinson's disease. In serve dopamine depletion, D2 stimulation alone appears to be insufficient to restore normal movement. Quinpirole, but not SKF 38393, elicited paroxysmal limb/ body jerking in reserpine‐AMPT‐treated rats, providing further evidence that atypical jerking can be elicited by D2 stimulation in the complete absence of D1 stimulation. This laboratory observation suggests that some jerking dyskinesias seen in treated parkinsonian patients may be mediated by an imbalance in D1‐D2 receptor stimulation.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>C. Anthony Hubbard</name><affiliations><json:string>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</json:string></affiliations></json:item><json:item><name>Dr. Trugman</name><affiliations><json:string>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>α‐Methyl‐p‐tyrosine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Catalepsy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>D1 and D2 dopamine agonist</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Rat</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Reserpine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinsonism</value></json:item></subject><language><json:string>eng</json:string></language><abstract>To gain insight into the antiparkinsonian effects of selective D1 and D2 dopamine receptor stimulation, we examined the ability of D1 (SKF 38393) and D2 (quinpirole) agonists to reverse catalepsy induced by the combined administration of reserpine and α‐methyl‐p‐tyrosine (AMPT) in rats. Catalepsy, the failure to correct an externally imposed posture, is a measure of akinesia and was assessed using the bar test. Rats injected with reserpine alone (2.5 mg/ kg i.p.) developed akinesia and ptosis within 60‐90 min. The D1 agonist SKF 38393 (30 mg/ kg i.v.) rapidly reversed ptosis and restored near‐normal mobility when administered 24 h after reserpine and AMPT; catalepsy was reversed for 90 min, after which the drug effect wore off. Quinpirole (1 mg/ kg i.v.) reversed catalepsy for the duration of the test period (4 h) but did not consistently reverse ptosis or promote normal mobility; the rats continued to exhibit kyphotic postures with little spontaneous locomotion. These results indicate that selective D1 stimulation is sufficient to reverse reserpine‐induced akinesia and highlight the need for the development of potent selective D1 agonists for clincal traial in Parkinson's disease. In serve dopamine depletion, D2 stimulation alone appears to be insufficient to restore normal movement. Quinpirole, but not SKF 38393, elicited paroxysmal limb/ body jerking in reserpine‐AMPT‐treated rats, providing further evidence that atypical jerking can be elicited by D2 stimulation in the complete absence of D1 stimulation. This laboratory observation suggests that some jerking dyskinesias seen in treated parkinsonian patients may be mediated by an imbalance in D1‐D2 receptor stimulation.</abstract><qualityIndicators><score>6.708</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1701</abstractCharCount><pdfWordCount>3708</pdfWordCount><pdfCharCount>22650</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>254</abstractWordCount></qualityIndicators><title>Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title><genre><json:string>Serial article</json:string></genre><host><volume>8</volume><pages><total>6</total><last>478</last><first>473</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Review</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1993</publicationDate><copyrightDate>1993</copyrightDate><doi><json:string>10.1002/mds.870080410</json:string></doi><id>A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1993</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title><author><persName><forename type="first">C. Anthony</forename><surname>Hubbard</surname></persName><affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</affiliation></author><author><persName><surname>Trugman</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Box 394, University of Virginia Health Sciences Center, Charlottesville, V A 22908, U.S.A</p></note><affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1993"></date><biblScope unit="vol">8</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="473">473</biblScope><biblScope unit="page" to="478">478</biblScope></imprint></monogr><idno type="istex">A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2</idno><idno type="DOI">10.1002/mds.870080410</idno><idno type="ArticleID">MDS870080410</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1993</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>To gain insight into the antiparkinsonian effects of selective D1 and D2 dopamine receptor stimulation, we examined the ability of D1 (SKF 38393) and D2 (quinpirole) agonists to reverse catalepsy induced by the combined administration of reserpine and α‐methyl‐p‐tyrosine (AMPT) in rats. Catalepsy, the failure to correct an externally imposed posture, is a measure of akinesia and was assessed using the bar test. Rats injected with reserpine alone (2.5 mg/ kg i.p.) developed akinesia and ptosis within 60‐90 min. The D1 agonist SKF 38393 (30 mg/ kg i.v.) rapidly reversed ptosis and restored near‐normal mobility when administered 24 h after reserpine and AMPT; catalepsy was reversed for 90 min, after which the drug effect wore off. Quinpirole (1 mg/ kg i.v.) reversed catalepsy for the duration of the test period (4 h) but did not consistently reverse ptosis or promote normal mobility; the rats continued to exhibit kyphotic postures with little spontaneous locomotion. These results indicate that selective D1 stimulation is sufficient to reverse reserpine‐induced akinesia and highlight the need for the development of potent selective D1 agonists for clincal traial in Parkinson's disease. In serve dopamine depletion, D2 stimulation alone appears to be insufficient to restore normal movement. Quinpirole, but not SKF 38393, elicited paroxysmal limb/ body jerking in reserpine‐AMPT‐treated rats, providing further evidence that atypical jerking can be elicited by D2 stimulation in the complete absence of D1 stimulation. This laboratory observation suggests that some jerking dyskinesias seen in treated parkinsonian patients may be mediated by an imbalance in D1‐D2 receptor stimulation.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>α‐Methyl‐p‐tyrosine</term></item><item><term>Catalepsy</term></item><item><term>D1 and D2 dopamine agonist</term></item><item><term>Rat</term></item><item><term>Reserpine</term></item><item><term>Parkinsonism</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1993">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v8:4</doi><numberingGroup><numbering type="journalVolume" number="8">8</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="1993">1993</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870080410</doi><idGroup><id type="unit" value="MDS870080410"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 1993 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">473</numbering><numbering type="pageLast">478</numbering></numberingGroup><correspondenceTo>Department of Neurology, Box 394, University of Virginia Health Sciences Center, Charlottesville, V A 22908, U.S.A</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870080410.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="32"></count></countGroup><titleGroup><title type="main" xml:lang="en">Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title><title type="short" xml:lang="en">REVERSAL OF CATALEPSY BY D1 AND D2 AGONISTS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>C. Anthony</givenNames><familyName>Hubbard</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Joel M.</givenNames><familyName>Trugman</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">α‐Methyl‐<i>p</i>‐tyrosine</keyword><keyword xml:id="kwd2">Catalepsy</keyword><keyword xml:id="kwd3">D1 and D2 dopamine agonist</keyword><keyword xml:id="kwd4">Rat</keyword><keyword xml:id="kwd5">Reserpine</keyword><keyword xml:id="kwd6">Parkinsonism</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>To gain insight into the antiparkinsonian effects of selective D1 and D2 dopamine receptor stimulation, we examined the ability of D1 (SKF 38393) and D2 (quinpirole) agonists to reverse catalepsy induced by the combined administration of reserpine and α‐methyl‐p‐tyrosine (AMPT) in rats. Catalepsy, the failure to correct an externally imposed posture, is a measure of akinesia and was assessed using the bar test. Rats injected with reserpine alone (2.5 mg/ kg i.p.) developed akinesia and ptosis within 60‐90 min. The D1 agonist SKF 38393 (30 mg/ kg i.v.) rapidly reversed ptosis and restored near‐normal mobility when administered 24 h after reserpine and AMPT; catalepsy was reversed for 90 min, after which the drug effect wore off. Quinpirole (1 mg/ kg i.v.) reversed catalepsy for the duration of the test period (4 h) but did not consistently reverse ptosis or promote normal mobility; the rats continued to exhibit kyphotic postures with little spontaneous locomotion. These results indicate that selective D1 stimulation is sufficient to reverse reserpine‐induced akinesia and highlight the need for the development of potent selective D1 agonists for clincal traial in Parkinson's disease. In serve dopamine depletion, D2 stimulation alone appears to be insufficient to restore normal movement. Quinpirole, but not SKF 38393, elicited paroxysmal limb/ body jerking in reserpine‐AMPT‐treated rats, providing further evidence that atypical jerking can be elicited by D2 stimulation in the complete absence of D1 stimulation. This laboratory observation suggests that some jerking dyskinesias seen in treated parkinsonian patients may be mediated by an imbalance in D1‐D2 receptor stimulation.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>REVERSAL OF CATALEPSY BY D1 AND D2 AGONISTS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists</title></titleInfo><name type="personal"><namePart type="given">C. Anthony</namePart><namePart type="family">Hubbard</namePart><affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Trugman</namePart><affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville, Virginia, U.S.A.</affiliation><description>Correspondence: Department of Neurology, Box 394, University of Virginia Health Sciences Center, Charlottesville, V A 22908, U.S.A</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">reviewArticle</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1993</dateIssued><copyrightDate encoding="w3cdtf">1993</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="references">32</extent></physicalDescription><abstract lang="en">To gain insight into the antiparkinsonian effects of selective D1 and D2 dopamine receptor stimulation, we examined the ability of D1 (SKF 38393) and D2 (quinpirole) agonists to reverse catalepsy induced by the combined administration of reserpine and α‐methyl‐p‐tyrosine (AMPT) in rats. Catalepsy, the failure to correct an externally imposed posture, is a measure of akinesia and was assessed using the bar test. Rats injected with reserpine alone (2.5 mg/ kg i.p.) developed akinesia and ptosis within 60‐90 min. The D1 agonist SKF 38393 (30 mg/ kg i.v.) rapidly reversed ptosis and restored near‐normal mobility when administered 24 h after reserpine and AMPT; catalepsy was reversed for 90 min, after which the drug effect wore off. Quinpirole (1 mg/ kg i.v.) reversed catalepsy for the duration of the test period (4 h) but did not consistently reverse ptosis or promote normal mobility; the rats continued to exhibit kyphotic postures with little spontaneous locomotion. These results indicate that selective D1 stimulation is sufficient to reverse reserpine‐induced akinesia and highlight the need for the development of potent selective D1 agonists for clincal traial in Parkinson's disease. In serve dopamine depletion, D2 stimulation alone appears to be insufficient to restore normal movement. Quinpirole, but not SKF 38393, elicited paroxysmal limb/ body jerking in reserpine‐AMPT‐treated rats, providing further evidence that atypical jerking can be elicited by D2 stimulation in the complete absence of D1 stimulation. This laboratory observation suggests that some jerking dyskinesias seen in treated parkinsonian patients may be mediated by an imbalance in D1‐D2 receptor stimulation.</abstract><subject lang="en"><genre>Keywords</genre><topic>α‐Methyl‐p‐tyrosine</topic><topic>Catalepsy</topic><topic>D1 and D2 dopamine agonist</topic><topic>Rat</topic><topic>Reserpine</topic><topic>Parkinsonism</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>473</start><end>478</end><total>6</total></extent></part></relatedItem><identifier type="istex">A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2</identifier><identifier type="DOI">10.1002/mds.870080410</identifier><identifier type="ArticleID">MDS870080410</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1993 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000F75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A3A8C0823B3FB678772FBBB4AE1D70BADB8CADA2
|texte= Reversal of reserpine‐induced catalepsy by selective D1 and D2 dopamine agonists
}}
| This area was generated with Dilib version V0.6.23. |  |